Cero Therapeutics to present data from Phase 2 trial of CER-1236

CERo Therapeutics (CERO) announces a presentation highlighting data to date from the Company’s Phase 1 clinical trial, called CERTAIN-T, of its lead compound, CER-1236. Reflective of the Company’s recent clinical update, the data highlight results from the first cohort of the trial, featuring a positive safety and tolerability profile, and rapid in vivo cell expansion, with observed approximately 20-70-fold expansion, peaking between days 7-14, followed by prolonged persistence. The data presentation also includes outcomes from an index patient with acute myeloid leukemia, AML, that progressed from myelodysplastic syndrome, MDS, who received a total of four CER-1236 infusions over 5 months at the lowest dose level. Prior to treatment with CER-1236, the patient required frequent platelet transfusions, but after treatment he developed transfusion independence lasting over two months. The data are being presented at the Tandem Meeting of the American Society of Transplantation and Cellular Therapy, ASTCT, and the Center for International Blood and Marrow Transplant Research, CIBMTR, meeting in Salt Lake City, Utah, February 4-6, 2026.